AKS-699

AKS-699 is a recombinant Fc-fusion protein developed by Akston Biosciences using its proprietary Ambifect™ technology for the treatment of canine atopic dermatitis. The therapeutic is designed to specifically bind and neutralize Interleukin-31 (IL-31), a key cytokine implicated in the pathophysiology of allergic skin diseases in dogs. IL-31 is known to be a primary mediator of pruritus (itching) and inflammation; by sequestering this cytokine, AKS-699 aims to break the itch-scratch cycle and provide long-lasting symptomatic relief. The Ambifect platform allows for the creation of protein therapeutics with extended half-lives and simplified manufacturing processes, potentially offering a cost-effective and convenient alternative to existing monoclonal antibody therapies.